TD Cowen Cuts Enovix (NASDAQ:ENVX) Price Target to $7.50

Enovix (NASDAQ:ENVX) had its target price decreased by TD Cowen from $15.00 to $7.50 in a report released on Thursday morning, Marketbeat Ratings reports. TD Cowen currently has a hold rating on the stock.

Other equities analysts also recently issued reports about the company. Northland Securities set a $16.00 price objective on Enovix in a research note on Monday, November 17th. JPMorgan Chase & Co. dropped their price target on Enovix from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Wednesday, November 12th. Cantor Fitzgerald decreased their price objective on shares of Enovix from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovix in a research note on Monday, December 29th. Finally, Oppenheimer set a $24.00 target price on shares of Enovix in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Enovix presently has an average rating of “Moderate Buy” and a consensus target price of $15.65.

Enovix Trading Down 11.4%

Shares of Enovix stock opened at $5.27 on Thursday. The company has a 50-day moving average of $7.10 and a two-hundred day moving average of $8.88. Enovix has a 12-month low of $5.24 and a 12-month high of $16.49. The company has a current ratio of 9.72, a quick ratio of 9.47 and a debt-to-equity ratio of 1.74. The stock has a market cap of $1.14 billion, a PE ratio of -6.84 and a beta of 2.13.

Institutional Investors Weigh In On Enovix

Several hedge funds have recently modified their holdings of the company. Caitlin John LLC purchased a new stake in shares of Enovix during the third quarter worth about $27,000. Parallel Advisors LLC grew its stake in Enovix by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 3,926 shares of the company’s stock worth $39,000 after acquiring an additional 1,342 shares during the period. CWM LLC raised its holdings in Enovix by 95.4% in the 4th quarter. CWM LLC now owns 6,081 shares of the company’s stock valued at $44,000 after acquiring an additional 2,969 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Enovix during the 4th quarter worth $72,000. Finally, Bowman & Co S.C. acquired a new stake in shares of Enovix during the fourth quarter worth $73,000. 50.92% of the stock is owned by institutional investors and hedge funds.

Enovix News Roundup

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Q4 results beat expectations: revenue of ~$11.3M (+~16% YoY) topped estimates and EPS/loss was slightly better than forecast; gross profit and operating-loss improvement were highlighted on the call — a fundamental bright spot supporting longer‑term growth potential. SA Q4 Presentation
• Positive Sentiment: Multiple outlets noted the revenue and EPS beats and operational improvement (higher gross profit, narrower operating loss), which help the growth narrative even as profitability remains distant. Yahoo Finance: Q4 Report
• Neutral Sentiment: Unusual options activity: a large block of call buying (≈31,896 calls) indicates speculative/leveraged interest that may amplify intraday moves but doesn’t change fundamentals. AAII Options Note
• Neutral Sentiment: Some analysts lowered price targets but kept constructive ratings (e.g., Canaccord trimmed its PT but remains “Buy”), which mutes upside while signaling continued long‑term conviction from parts of the sell‑side. Benzinga: Canaccord Note
• Negative Sentiment: Near‑term guidance disappointed: Q1 FY2026 revenue guidance ($6.5M–$7.5M) came in well below consensus (~$8.8M), a key proximate reason for selling pressure as it implies slower near‑term growth. Company Press Release / Deck
• Negative Sentiment: Analyst downgrades/target cuts: TD Cowen cut its target sharply and moved to “Hold,” and other firms trimmed targets — increasing near‑term downside risk as sell‑side expectations are reset. Benzinga: TD Cowen Note
• Negative Sentiment: New risk disclosure highlights rising geopolitical/trade exposure (U.S.–China tensions) that could pressure supply chains and margins — a fresh governance/operational risk investors must price in. TipRanks: Risk Disclosure
• Negative Sentiment: Balance‑sheet and liquidity signals are concerning to some investors: cash fell year‑over‑year and total liabilities rose materially; coupled with insider sales called out in reporting, that has likely amplified selling. Quiver Quant: Financials

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.